Exact Sciences Cor (EXAS) 21.46 $EXAS Exact Sci
Post# of 273254
Posted On: 09/22/2016 5:16:01 AM
Exact Sciences Cor (EXAS) 21.46 $EXAS
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
PR Newswire - Fri Sep 16, 3:15PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 24,119 shares of common stock to 18 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4). The Company is making this announcement as required by NASDAQ rules.
EXAS: 21.46 (+0.56)
Healthcare Stocks Under Review -- Exact Sciences, Great Basin Scientific, Agilent Technologies, and Thermo Fisher Scientific
PR Newswire - Thu Sep 08, 6:30AM CDT
The Medical Laboratories market continues to grow at a fast pace due to scientific advances and aging population. This segment includes bacteriological, histological, pathological and chemical analysis, urinalysis, and dental and medical X-rays. Stocks under assessment on Stock-Callers.com today are: Exact Sciences Corp. (NASDAQ: EXAS), Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher Scientific Inc. (NYSE: TMO). Learn more about these stocks by downloading their free research reports in PDF format at:
GBSN: 3.42 (-0.36), TMO: 155.42 (+3.80), A: 46.04 (+0.33), EXAS: 21.46 (+0.56)
Exact Sciences to participate in the Baird 2016 Global Healthcare Conference
PR Newswire - Tue Aug 30, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in Baird's 2016 Global Healthcare Conference.
EXAS: 21.46 (+0.56)
Exact Sciences (EXAS): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:42AM CDT
Exact Sciences (EXAS) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry.
EXAS: 21.46 (+0.56)
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:30AM CDT
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
AMKR: 9.22 (+0.33), CC: 14.74 (+0.63), EXAS: 21.46 (+0.56), AAPL: 113.55 (-0.02), PBYI: 67.97 (+2.81)
4 Biggest Winners from This Earnings Season
Swarup Gupta - Zacks Investment Research - Thu Aug 18, 1:39PM CDT
Though both earnings and revenues continue to decline year-over-year, results have improved from the preceding quarter.
AMKR: 9.22 (+0.33), CC: 14.74 (+0.63), EXAS: 21.46 (+0.56), AAPL: 113.55 (-0.02), PBYI: 67.97 (+2.81)
CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries without Cost Sharing
PR Newswire - Mon Aug 15, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced that the Centers for Medicare and Medicaid Services (CMS) issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of Cologuard every three years without patient coinsurance, copayments or deductibles.
EXAS: 21.46 (+0.56)
Cologuard® Coverage Expands with Updated Policies from HCSC and Florida Blue
PR Newswire - Thu Aug 11, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Health Care Service Corp. (HCSC), the nation's fourth largest health insurer, and Florida Blue recently updated their medical policies to cover Cologuard. With these policy updates, 80 million people are insured by commercial plans with positive medical policies regarding Cologuard. Including Medicare, Cologuard is now covered for 62 percent of its total target population.
EXAS: 21.46 (+0.56)
EXAS: A Biotech Stock Screening to Prevent Colorectal Cancer
Maher Syed - Zacks Investment Research - Mon Aug 08, 5:25PM CDT
Exact Sciences looks like a potent investment candidate over the long run, and here's why.
EXAS: 21.46 (+0.56)
Exact Sciences to participate in Canaccord Genuity 36th Annual Growth Conference
PR Newswire - Mon Aug 08, 9:57AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Canaccord Genuity 36th Annual Growth Conference.
EXAS: 21.46 (+0.56)
Exact Sciences Announces Upsizing and Pricing of Public Offering of Common Stock
PR Newswire - Thu Jul 28, 7:00AM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced the upsizing and pricing of its previously announced underwritten public offering of common stock. The Company is selling 8,500,000 shares of common stock through the underwriters at a public offering price of $15.50 per share. The offering was increased to 8,500,000 shares from the previously announced offering of 7,000,000 shares due to market demand. The Company has also granted the underwriters an option to purchase up to 1,275,000 additional shares. The offering is being underwritten by Jefferies LLC and Robert W. Baird & Co. Incorporated, as joint book-running managers of the offering, and Canaccord Genuity Inc., as co-manager of the offering, and is expected to close on or about August 2, 2016, subject to customary closing conditions.
EXAS: 21.46 (+0.56)
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
BusinessWire - Wed Jul 27, 3:01PM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W. Baird & Co. Incorporated and Canaccord Genuity Inc. as underwriters in an underwritten public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"
on Form S-3. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares.
EXAS: 21.46 (+0.56)
Exact Sciences Has Returned 52.1% Since SmarTrend Recommendation (EXAS)
Comtex SmarTrend(R) - Tue Jun 21, 12:17AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on June 6th, 2016 at $7.13. In approximately 2 weeks, Exact Sciences has returned 52.14% as of today's recent price of $10.84.
EXAS: 21.46 (+0.56)
Upgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Fri Jun 17, 3:11AM CDT
Exact Sciences (NASDAQ:EXAS) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $11.25 on volume of 36.6 million shares, above average daily volume of 1.9 million. EXACT Sciences Corporation is an applied genomics company that develops and commercializes proprietary DNA-based tests for the early detection of cancer. The Company's PreGen-Plus is intended for the early detection of colorectal cancer in the average-risk population.
EXAS: 21.46 (+0.56)
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 5.54% Rise
Comtex SmarTrend(R) - Wed Jun 15, 11:45AM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $9.73 to a high of $11.24. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $9.73 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 21.46 (+0.56)
Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
PR Newswire - Fri Jun 03, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president, business development and strategy, effective June 20, 2016. In his new role, Mr. Elliott will oversee the identification and pursuit of strategic business opportunities, while also helping drive Cologuard's continued success.
EXAS: 21.46 (+0.56)
Exact Sciences to participate in three investor conferences during June
PR Newswire - Wed Jun 01, 3:15PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June.
EXAS: 21.46 (+0.56)
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
PR Newswire - Wed Jun 01, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
EXAS: 21.46 (+0.56)
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
PR Newswire - Fri Sep 16, 3:15PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 24,119 shares of common stock to 18 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4). The Company is making this announcement as required by NASDAQ rules.
EXAS: 21.46 (+0.56)
Healthcare Stocks Under Review -- Exact Sciences, Great Basin Scientific, Agilent Technologies, and Thermo Fisher Scientific
PR Newswire - Thu Sep 08, 6:30AM CDT
The Medical Laboratories market continues to grow at a fast pace due to scientific advances and aging population. This segment includes bacteriological, histological, pathological and chemical analysis, urinalysis, and dental and medical X-rays. Stocks under assessment on Stock-Callers.com today are: Exact Sciences Corp. (NASDAQ: EXAS), Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher Scientific Inc. (NYSE: TMO). Learn more about these stocks by downloading their free research reports in PDF format at:
GBSN: 3.42 (-0.36), TMO: 155.42 (+3.80), A: 46.04 (+0.33), EXAS: 21.46 (+0.56)
Exact Sciences to participate in the Baird 2016 Global Healthcare Conference
PR Newswire - Tue Aug 30, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in Baird's 2016 Global Healthcare Conference.
EXAS: 21.46 (+0.56)
Exact Sciences (EXAS): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:42AM CDT
Exact Sciences (EXAS) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry.
EXAS: 21.46 (+0.56)
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:30AM CDT
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
AMKR: 9.22 (+0.33), CC: 14.74 (+0.63), EXAS: 21.46 (+0.56), AAPL: 113.55 (-0.02), PBYI: 67.97 (+2.81)
4 Biggest Winners from This Earnings Season
Swarup Gupta - Zacks Investment Research - Thu Aug 18, 1:39PM CDT
Though both earnings and revenues continue to decline year-over-year, results have improved from the preceding quarter.
AMKR: 9.22 (+0.33), CC: 14.74 (+0.63), EXAS: 21.46 (+0.56), AAPL: 113.55 (-0.02), PBYI: 67.97 (+2.81)
CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries without Cost Sharing
PR Newswire - Mon Aug 15, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced that the Centers for Medicare and Medicaid Services (CMS) issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of Cologuard every three years without patient coinsurance, copayments or deductibles.
EXAS: 21.46 (+0.56)
Cologuard® Coverage Expands with Updated Policies from HCSC and Florida Blue
PR Newswire - Thu Aug 11, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Health Care Service Corp. (HCSC), the nation's fourth largest health insurer, and Florida Blue recently updated their medical policies to cover Cologuard. With these policy updates, 80 million people are insured by commercial plans with positive medical policies regarding Cologuard. Including Medicare, Cologuard is now covered for 62 percent of its total target population.
EXAS: 21.46 (+0.56)
EXAS: A Biotech Stock Screening to Prevent Colorectal Cancer
Maher Syed - Zacks Investment Research - Mon Aug 08, 5:25PM CDT
Exact Sciences looks like a potent investment candidate over the long run, and here's why.
EXAS: 21.46 (+0.56)
Exact Sciences to participate in Canaccord Genuity 36th Annual Growth Conference
PR Newswire - Mon Aug 08, 9:57AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the Canaccord Genuity 36th Annual Growth Conference.
EXAS: 21.46 (+0.56)
Exact Sciences Announces Upsizing and Pricing of Public Offering of Common Stock
PR Newswire - Thu Jul 28, 7:00AM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced the upsizing and pricing of its previously announced underwritten public offering of common stock. The Company is selling 8,500,000 shares of common stock through the underwriters at a public offering price of $15.50 per share. The offering was increased to 8,500,000 shares from the previously announced offering of 7,000,000 shares due to market demand. The Company has also granted the underwriters an option to purchase up to 1,275,000 additional shares. The offering is being underwritten by Jefferies LLC and Robert W. Baird & Co. Incorporated, as joint book-running managers of the offering, and Canaccord Genuity Inc., as co-manager of the offering, and is expected to close on or about August 2, 2016, subject to customary closing conditions.
EXAS: 21.46 (+0.56)
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
BusinessWire - Wed Jul 27, 3:01PM CDT
Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W. Baird & Co. Incorporated and Canaccord Genuity Inc. as underwriters in an underwritten public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC"
on Form S-3. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares. EXAS: 21.46 (+0.56)
Exact Sciences Has Returned 52.1% Since SmarTrend Recommendation (EXAS)
Comtex SmarTrend(R) - Tue Jun 21, 12:17AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on June 6th, 2016 at $7.13. In approximately 2 weeks, Exact Sciences has returned 52.14% as of today's recent price of $10.84.
EXAS: 21.46 (+0.56)
Upgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Fri Jun 17, 3:11AM CDT
Exact Sciences (NASDAQ:EXAS) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $11.25 on volume of 36.6 million shares, above average daily volume of 1.9 million. EXACT Sciences Corporation is an applied genomics company that develops and commercializes proprietary DNA-based tests for the early detection of cancer. The Company's PreGen-Plus is intended for the early detection of colorectal cancer in the average-risk population.
EXAS: 21.46 (+0.56)
Look for Shares of Exact Sciences to Potentially Pullback after Yesterday's 5.54% Rise
Comtex SmarTrend(R) - Wed Jun 15, 11:45AM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $9.73 to a high of $11.24. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $9.73 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXAS: 21.46 (+0.56)
Exact Sciences Appoints Jeff Elliott to Lead Business Development & Strategy
PR Newswire - Fri Jun 03, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president, business development and strategy, effective June 20, 2016. In his new role, Mr. Elliott will oversee the identification and pursuit of strategic business opportunities, while also helping drive Cologuard's continued success.
EXAS: 21.46 (+0.56)
Exact Sciences to participate in three investor conferences during June
PR Newswire - Wed Jun 01, 3:15PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during June.
EXAS: 21.46 (+0.56)
Cologuard Available In-Network for Anthem Blue Cross and Blue Shield Members in Five Additional Midwest States
PR Newswire - Wed Jun 01, 5:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) announced today that under a recently-signed contract, Exact Sciences is now an in-network provider of Cologuard with Anthem Blue Cross and Blue Shield in the states of Indiana, Ohio, Kentucky, Missouri and Wisconsin.
EXAS: 21.46 (+0.56)
(0)
(0)Scroll down for more posts ▼